BIOC51, a potential nitric oxide-based treatment of chronic pulmonary infections due to Pseudomonas aeruginosa bacteria in patients with cystic fibrosis (CF),was awarded special status…
Articles by Janet Stewart, MSc
Vertex Pharmaceuticals announced it will double the number of “All in for CF Scholarships” this year to help more people…
Vizient, which calls itself the nation’s “largest member-driven health care performance improvement company,” has awarded a contract for  Alcresta’s…
Cystic Fibrosis Foundation Therapeutics has given Pulmatrix a grant to test the safety of PUR1900 as a treatment for allergic bronchopulmonary aspergillosis (ABPA)…
An influential group of European cystic fibrosis experts has signed off on the design of a Phase 3 clinical trial…
Researchers found a new defect called the R248G mutation in the CFTR gene in three Spanish siblings whose diagnoses indicate…
A significant number of cystic fibrosis (CF) patients do not receive timely lung transplant evaluations because of their preference and…